Breaking News Instant updates and real-time market news.

REGN

Regeneron

$302.51

-2.3 (-0.75%)

, NVS

Novartis

$82.02

-0.7 (-0.85%)

16:31
05/20/19
05/20
16:31
05/20/19
16:31

Regeneron initiated with a Neutral at Credit Suisse

Credit Suisse analyst Evan Seigerman started Regeneron Pharmaceuticals (REGN) with a Neutral rating and $336 price target. The analyst is concerned that Eylea could face "increasing headwinds" with the upcoming launch of Novartis' (NVS) brolucizumab. Further, he believes consensus estimates for the Sanofi (SNY) collaboration may be too high.

REGN

Regeneron

$302.51

-2.3 (-0.75%)

NVS

Novartis

$82.02

-0.7 (-0.85%)

SNY

Sanofi

$41.40

-0.53 (-1.26%)

  • 20

    May

  • 23

    May

  • 31

    May

  • 14

    Jun

  • 26

    Jun

REGN Regeneron
$302.51

-2.3 (-0.75%)

05/08/19
BMOC
05/08/19
NO CHANGE
Target $375
BMOC
Market Perform
Regeneron price target lowered to $375 from $412 at BMO Capital
BMO Capital analyst Matthew Luchini lowered his price target on Regeneron (REGN) to $375 after its "uninspiring" Q1 driven by higher R&D costs and lower collaboration revenue with Sanofi (SNY). The analyst notes that while the company's Dupixent is "showing progress" and Eylea's 8% revenue growth is a positive, he is also concerned with higher discounting for the latter along with the potential for a more competitive vascular endothelial growth factor, or VEGF, landscape. Luchini keeps his Market Perform rating on Regeneron.
05/13/19
CANT
05/13/19
NO CHANGE
Target $405
CANT
Neutral
Regeneron price target lowered to $405 from $441 at Cantor Fitzgerald
Cantor Fitzgerald analyst Regeneron Pharmaceuticals (REGN) to $405 from $441 saying the company's expenses are tracking higher than his projections. Further, he thinks investor concerns about Novartis' (NVS) brolucizumab approval in eye and increased atopic dermatitis competition remain headwinds for share upside. The analyst reiterates a Neutral rating on Regeneron following its Q1 results.
05/20/19
LEHM
05/20/19
NO CHANGE
Target $315
LEHM
Underweight
Barclays still bearish on Regeneron despite 18% drop year-to-date
Barclays analyst Geoff Meacham says that despite the 18% decline of Regeneron Pharmaceuticals shares year-to-date, he remains bearish on the name with an Underweight rating and $315 price target. The analyst cites Eylea concentration risk and the near/long-term competitive threat in wet age-related macular degeneration. Pricing and/or share erosion in wet AMD from brolucizumab or DARPin could yield worse than consensus expectations, Meacham tells investors in a research note.
05/16/19
JPMS
05/16/19
NO CHANGE
Target $395
JPMS
Neutral
Regeneron selloff brings improved risk/reward, says JPMorgan
JPMorgan analyst Cory Kasimov keeps a Neutral rating on shares of Regeneron Pharmaceuticals buy says the stock's risk/reward is improved following the recent sharp pullback. The analyst adds that feedback from five doctors supports his above-consensus estimates for Dupixent. Kasimov currently models peak sales north of $7B across atopic dermatitis, asthma, and nasal polyps in the U.S. and Europe, "with everything else left as upside." Every $1B in total Dupixent revenue results in a $20 impact to the stock's fair valuation, the analyst tells investors in a research note titled "Dupi...How Big Is Big?"
NVS Novartis
$82.02

-0.7 (-0.85%)

05/17/19
FBCO
05/17/19
NO CHANGE
Target $68
FBCO
Outperform
Alcon off to 'solid start' post-Novartis spin, says Credit Suisse
Credit Suisse analyst Matt Miksic reiterated an Outperform rating on Alcon (ALC) and raised his price target to $68 from $66 following the company's quarterly results, saying Alcon is off to a "solid start" following the spinoff from Novartis (NVS), and says he is incrementally more bullish on the company's revenue and growth drivers.
05/13/19
WELS
05/13/19
NO CHANGE
WELS
Lawsuit against Teva, others to hit generic drug stocks, says Wells Fargo
Wells Fargo analyst David Maris believes the lawsuit by 44 states against 20 generic drugmakers will weigh on generic drug stocks this week and remain an "overhang issue for some time." Actual penalties and damages are impossible to calculate, but could be material, Maris tells investors in a research note. The analyst spoke to the Connecticut attorney general's office this morning and learned they are preparing for trial in these cases. Language the attorney general has used, such as "unprecedented" and his desire to clawback all gains from collusion, should be indicative of the states' intent, Maris writes. He believes that for a sector that is generally highly levered, and with some companies named already facing an overhang from opioid litigation like Teva (TEVA), this is "especially unwelcome news."
05/20/19
RBCM
05/20/19
NO CHANGE
RBCM
RBC says posting hints at Zolgensma label potentially positive for PTC, Biogen
RBC Capital analyst Brian Abrahams noted a new posting on ClinicalTrials.gov that he said "looks like" an expanded access program for Zolgensma that he believes could possibly offer some hints as to the potential label under discussion with the FDA. The most interesting parts are the inclusion criteria, which he thinks could "represent a middle ground" in terms of the breadth of label Novartis (NVS) could obtain for the drug. If the posting is predictive of Zolgensma's initial label, he said he would see it as an incremental positive for Biogen (BIIB), as it would potentially reduce the worst-case scenario of Zolgensma being approved with no age or weight restrictions. It would also be an incremental positive for PTC Therapeutics (PTCT), which Abrahams noted is looking to enter the space.
SNY Sanofi
$41.40

-0.53 (-1.26%)

02/26/19
MSCO
02/26/19
NO CHANGE
Target $215
MSCO
Overweight
Morgan Stanley says Sanofi, Regeneron face 'uphill battle' in Amgen patent fight
After a Delaware district court ruled in favor of Amgen (AMGN) upholding the validity of patents on PCSK9 antibodies in litigation versus Sanofi (SNY) and Regeneron (REGN), Morgan Stanley analyst Matthew Harrison said he believes Sanofi and Regeneron face an "uphill battle" given this was the second district court trial to find in favor of Amgen. Harrison, who said he expects "no acute impact" to Amgen or Regeneron shares given the limited recent investor focus on PCSK9 uptake, keeps an Overweight rating on Amgen shares.
02/26/19
JEFF
02/26/19
NO CHANGE
JEFF
The Medicines Co. may have only PCSK9 not infringing Amgen, says Jefferies
Following yesterday's patent win over Sanofi (SNY) and Regeneron (REGN), Amgen (AMGN) now possesses broad patents which will be difficult for most competitors to circumvent, Jefferies analyst Biren Amin tells investors in a research note. The Medicines Co.'s (MDCO) inclisiran, which falls outside of the claims as a purely RNA-directed agent, could be the only PCSK9 mechanism which does not infringe Amgen's Repatha, Amin contends. He believes that should Sanofi and Regeneron's Praluent be hit with a permanent injunction, inclisiran is "well positioned to carve out market share in a growing PCSK9 class."
03/20/19
SBSH
03/20/19
NO CHANGE
SBSH
Bayer shares likely to remain 'depressed' pending trial success, says Citi
While sentiment will "clearly take a knock" at the second Roundup trial going against Bayer (BAYRY), both verdicts were delivered by juries in California and EUR 22B of litigation risk is already priced into the shares, Citi analyst Peter Verdult tells investors in a research note. The analyst says his legal checks continue to instruct him to be more focused on the upcoming Hall vs. Monsanto trial being held in St Louis from April 1. He says that verdict will better determine whether his estimate of a potential settlement liability of $1B-$6B needs to be refined. However, Bayer shares will "likely remain depressed" until there is evidence of the company prevailing in one or more of the six cases to go to trial in 2019, Verdult contends. He keeps a Buy rating on the stock but prefers other Pharma plays AstraZeneca (AZN), Sanofi (SNY), Novartis (NVS) and Merck (MRK).

TODAY'S FREE FLY STORIES

FXI

iShares China Large-Cap ETF

$42.28

0.09 (0.21%)

10:20
07/17/19
07/17
10:20
07/17/19
10:20
Options
Short-term put buyer in China ETF bought delta neutral »

Short-term put buyer in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

10:17
07/17/19
07/17
10:17
07/17/19
10:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PAGS

PagSeguro Digital

$45.50

0.78 (1.74%)

, OPRA

Opera

$11.00

0.41 (3.87%)

10:16
07/17/19
07/17
10:16
07/17/19
10:16
Initiation
Fly Intel: Top five analyst initiations »

Catch up on today's…

PAGS

PagSeguro Digital

$45.50

0.78 (1.74%)

OPRA

Opera

$11.00

0.41 (3.87%)

WORK

Slack Technologies

$34.19

-0.24 (-0.70%)

JLL

Jones Lang LaSalle

$140.23

-0.06 (-0.04%)

ALSN

Allison Transmission

$47.46

-0.1 (-0.21%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

  • 06

    Aug

  • 06

    Aug

HSY

Hershey

$144.07

3.64 (2.59%)

, COP

ConocoPhillips

$60.31

0.57 (0.95%)

10:16
07/17/19
07/17
10:16
07/17/19
10:16
Upgrade
Fly Intel: Top five analyst upgrades »

Catch up on today's…

HSY

Hershey

$144.07

3.64 (2.59%)

COP

ConocoPhillips

$60.31

0.57 (0.95%)

CTRP

Ctrip

$38.35

1.48 (4.01%)

KBH

KB Home

$26.58

-0.16 (-0.60%)

SLGN

Silgan Holdings

$30.47

0.09 (0.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 25

    Jul

  • 30

    Jul

MFGP

Micro Focus

$21.23

0.57 (2.76%)

, WFC

Wells Fargo

$45.45

0.15 (0.33%)

10:16
07/17/19
07/17
10:16
07/17/19
10:16
Downgrade
Fly Intel: Top five analyst downgrades »

Catch up on today's…

MFGP

Micro Focus

$21.23

0.57 (2.76%)

WFC

Wells Fargo

$45.45

0.15 (0.33%)

ARLP

Alliance Resource Partners

$16.87

-0.38 (-2.20%)

WUBA

58.com

$57.07

-0.68 (-1.18%)

RL

Ralph Lauren

$111.09

-4.07 (-3.53%)

LEVI

Levi Strauss

$18.76

-1.05 (-5.30%)

PVH

PVH Corp.

$89.89

-2.61 (-2.82%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

  • 30

    Jul

  • 01

    Aug

  • 19

    Sep

  • 19

    Sep

  • 12

    Oct

  • 15

    Oct

$NYE

NYSE Market Internals

$0.00

(0.00%)

10:16
07/17/19
07/17
10:16
07/17/19
10:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DOYU

DouYu

$0.00

(0.00%)

10:15
07/17/19
07/17
10:15
07/17/19
10:15
Syndicate
Breaking Syndicate news story on DouYu »

DouYu indicated to open…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

LEVI

Levi Strauss

$18.74

-1.07 (-5.40%)

10:15
07/17/19
07/17
10:15
07/17/19
10:15
Options
Levi Strauss put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:15
07/17/19
07/17
10:15
07/17/19
10:15
General news
Fed funds futures have a light bid »

Fed funds futures have a…

10:15
07/17/19
07/17
10:15
07/17/19
10:15
General news
Breaking General news story  »

Week of 7/12 EIA…

DOYU

DouYu

$0.00

(0.00%)

10:13
07/17/19
07/17
10:13
07/17/19
10:13
Syndicate
Breaking Syndicate news story on DouYu »

DouYu indicated to open…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

DOYU

DouYu

$0.00

(0.00%)

10:09
07/17/19
07/17
10:09
07/17/19
10:09
Syndicate
Breaking Syndicate news story on DouYu »

DouYu indicated to open…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

DOYU

DouYu

$0.00

(0.00%)

10:05
07/17/19
07/17
10:05
07/17/19
10:05
Syndicate
DouYu indicated to open at $12.00, IPO priced at $11.50 »

DouYu (DOYU) priced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

TELL

Tellurian

$6.94

-0.74 (-9.64%)

10:05
07/17/19
07/17
10:05
07/17/19
10:05
Options
Tellurian call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

CTK

CooTek

$9.17

(0.00%)

10:00
07/17/19
07/17
10:00
07/17/19
10:00
Hot Stocks
CooTek falls -7.2% »

CooTek is down -7.2%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GWB

Great Western

$32.31

-2.69 (-7.69%)

10:00
07/17/19
07/17
10:00
07/17/19
10:00
Hot Stocks
Great Western falls -7.5% »

Great Western is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 10

    Sep

  • 11

    Sep

NUS

Nu Skin

$37.55

-7.95 (-17.47%)

10:00
07/17/19
07/17
10:00
07/17/19
10:00
Hot Stocks
Nu Skin falls -17.4% »

Nu Skin is down -17.4%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Aug

NM

Navios Maritime

$5.64

0.3 (5.62%)

10:00
07/17/19
07/17
10:00
07/17/19
10:00
Hot Stocks
Navios Maritime rises 5.8% »

Navios Maritime is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FSM

Fortuna Silver Mines

$3.36

0.185 (5.83%)

10:00
07/17/19
07/17
10:00
07/17/19
10:00
Hot Stocks
Fortuna Silver Mines rises 5.8% »

Fortuna Silver Mines is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ORN

Orion Group

$4.12

0.36 (9.57%)

10:00
07/17/19
07/17
10:00
07/17/19
10:00
Hot Stocks
Orion Group rises 9.3% »

Orion Group is up 9.3%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

TSLA

Tesla

$257.74

5.36 (2.12%)

09:57
07/17/19
07/17
09:57
07/17/19
09:57
Periodicals
Officials worry over Tesla's plan to unleash robo-cars, Washington Post says »

Tesla is racing to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 06

    Aug

ABT

Abbott

$86.34

3.23 (3.89%)

09:56
07/17/19
07/17
09:56
07/17/19
09:56
Hot Stocks
Abbott says 'running as fast as we can in Europe' »

Says: Has paid down a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

KKR

KKR

$26.05

0.01 (0.04%)

09:55
07/17/19
07/17
09:55
07/17/19
09:55
Options
KKR put volume heavy and directionally bearish »

Bearish flow noted in KKR…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

NCI

Navigant Consulting

$23.68

(0.00%)

09:55
07/17/19
07/17
09:55
07/17/19
09:55
Conference/Events
Senate Environment & Public Works Committee to hold a hearing »

The Senate Committee on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 19

    Sep

09:55
07/17/19
07/17
09:55
07/17/19
09:55
Conference/Events
House Transportation & Intrastructure Committee to hold a hearing »

The Subcommittee on…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.